Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum

HIV Clinical Trials

Volumn 10, Issue 1, 2009, Pages 41-47

  Bennetto Hood, Chantelle ^a   Bryson, Yvonne ^b   Stek, Alice ^c   King, Jennifer ^a   Mirochnick, Mark ^c   Acosta, Edward ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Amniotic fluid; Lamivudine; Nelfi navir; Zidovudine

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; ZIDOVUDINE;

ADULT; AMNION FLUID ANALYSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MASS SPECTROMETRY; MATERNAL SERUM; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 64949119971     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1001-41     Document Type: Article

References (28)

1. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries. JAMA. 2000;283:1175-1182.
2. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al., for the South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of Human Immunodefi ciency Virus Type 1. J Infect Dis. 2003;187:725-735.
3. Young AM, Allen CE, Audus KL. Effl ux transporters of the human placenta. Adv Drug Deliv Rev. 2003;55:125-132.
4. Gilbert WM, Brace RA. Amniotic fl uid volume and normal fl ows to and from the amniotic cavity. Semin Perinatol. 1993;17:150-157.
5. Remmel RP, Kawle SP, Weller D, Fletcher CV. Simultaneous HPLC assay for quantifi cation of indinavir, ritonavir, and saquinavir in human plasma. Clin Chem. 2000;46:73-81.
6. Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodefi ciency virus-infected children receiving combination therapy. Antimicrob Agents Chemother. 2000;44:1029-1034.
7. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternalfetal transfer and amniotic fl uid accumulation of lamivudine in Human Immunodefi ciency Virus-infected pregnant women. Am J Obstet Gynecol. 2001;184:153-158.
8. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, et al. Maternal-fetal transfer and amniotic fl uid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodefi ciency virus-infected pregnant women. Antimicrob Agents Chemother. 2004;48: 4332-4336.
9. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodefi ciency virus type 1. Antimicrob Agents Chemother. 2004;48:437-443.
10. Limoli KL, Trinh LH, Heilek-Snyder GM, Hellmann NS, Petropoulos CJ. Effects of human serum on protease inhibitor activity in a phenotypic drug susceptibility assay (Phenosense HIV). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA. Abstract 583-T.
11. Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, et al. Virologic response to nelfi navir-based regimens: Pharmacokinetics and drug resistance mutations (Viraphar study). AIDS. 2002;16:1331-1340.
12. Bardos P, Luthier B, Avenet JM, de Russe J, Muh JP, Soutoul JH, Weill JD. [Variations of the concentrations of certain glycoproteins in maternal serum, fetal serum and amniotic fluid during pregnancy] [in French]. Clin Chim Acta. 1976:66;353-363.
13. Bala S, Seth S, Seth PK. Albumin concentration in human amniotic fluid from normal pregnancies. Acta Paediatr Hung. 1987:28;187-192.
14. Chappuy J, Treluyer JM, Rey E, Dimet J, Fouche M, et al. Maternal-fetal transfer and amniotic fl uid accumulation of protease inhibitors in pregnant women who are infected with human immunodefi ciency virus. Am J Obstet Gynecol. 2004;191:558-562.
15. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T, and the Swiss Mother & Child HIV Cohort Study. Transplacental passage of protease inhibitors at delivery. AIDS. 2002;16:889-893.
16. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. J Pediatr Infect Dis. 2002;21:835-838.
17. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence of pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104:1441-1447.
18. Huisman MT, Smit JW, Wiltshire HR, Hoetelman RMW, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59:806-813.
19. Sudhakaran S, Ghabrail H, Nation RL, Kong DCM, Gude NM, Angus PW, Rayner CR. Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother. 2005;49:1023-1028.
20. Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, et al. Pharmacokinetic modelling of the placental transfer of nelfi navir and its M8 metabolite: A population study using 75 maternal-cord plasma samples. Br J Clin Pharmacol. 2007;64:634-644.
21. Gingelmaier A, Kurowski M, Kastner R, Eberle J, Mylonas I, Belohradsky BH, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20: 1737-1743.
22. Van Heeswijk RPG, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. The pharmacokinetics of nelfi navir and M8 during pregnancy and post partum. Clin Pharm Ther. 2004;76:588-597.
23. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308:965-974.
24. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Maenpaa J, Edwards RJ, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol. 1996;51:403-411.
25. Bonora S, Gonzalez de Requena D, Chiesa E, Maccabruni A, Forleo MA, Vichi F, et al., and the TARGET study group. Transplacental passage of tenofovir and other antiretrovirals at delivery. Presented at: 14th Annual Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 738a.
26. St-Pierre MV, Serrano MA, Macia RIR, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the mutidrug resistance protein family in human term placenta. Am J Phsiol Regul Integr Comp Physiol. 2000:279; R1495-1503.
27. Wijnholds J, Moi CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecifi c organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA. 2000:97; 7476-7481.
28. Mandelbrot L, Burgard M, Teglas JP, Benifl a JL, Kahn C, Blot P, et al. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers. AIDS. 1999;13:2143-2149.